• PRO
  • Events
  • About Blog Popular
  • Login
  • Register
  • PRO
  • Resources
    • Latest updates
    • Q&A
    • In-depth
    • In-house view
    • Practical resources
    • FromCounsel New
    • Commentary
  • Research tools
    • Global research hub
    • Lexy
    • Primary sources
    • Scanner
    • Research reports
  • Resources
  • Research tools
  • Learn
    • All
    • Webinars
    • Videos
  • Learn
  • Experts
    • Find experts
    • Influencers
    • Client Choice New
    • Firms
    • About
    Introducing Instruct Counsel
    The next generation search tool for finding the right lawyer for you.
  • Experts
  • My newsfeed
  • Events
  • About
  • Blog
  • Popular
  • Find experts
  • Influencers
  • Client Choice New
  • Firms
  • About
Introducing Instruct Counsel
The next generation search tool for finding the right lawyer for you.
  • Compare
  • Topics
  • Interviews
  • Guides

Analytics

Review your content's performance and reach.

  • Analytics dashboard
  • Top articles
  • Top authors
  • Who's reading?

Content Development

Become your target audience’s go-to resource for today’s hottest topics.

  • Trending Topics
  • Discover Content
  • Horizons
  • Ideation

Client Intelligence

Understand your clients’ strategies and the most pressing issues they are facing.

  • Track Sectors
  • Track Clients
  • Mandates
  • Discover Companies
  • Reports Centre

Competitor Intelligence

Keep a step ahead of your key competitors and benchmark against them.

  • Benchmarking
  • Competitor Mandates
Home

Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact [email protected]

Register

China amends its cornerstone Regulation on Medical Devices

Sidley Austin LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

If you can't read this PDF, you can view its text here. Go back to the PDF .

China April 7 2014

On March 31, 2014, China’s State Council published the amended Administrative Regulation on Medical Devices, which will become effective on June 1, 2014. The Regulation, since becoming effective in 2000, has been the cornerstone of China’s medical device regulatory system. The amended Regulation contains important revisions that will significantly impact the medical device industry in China.

  1. Expanded Definition 
    The amended Regulation expands the definition of medical devices to include new categories of products: “instrument, apparatus, appliance, in vitro reagent and calibrator, material and other similar or related article, including the necessary software, which are intended … (4) for the purpose of life support or maintenance … or (6) to collect information for diagnosis or treatment utilizing human sample testing.”
  2. Product Registration 
    The amended Regulation makes some significant changes to the current product registration regime for medical devices. Class I devices, including imported products, are no longer subject to registration, but rather a filing with the China Food and Drug Administration (CFDA) or its local counterparts; Class II and Class III devices continue to be subject to the same registration requirements. 

    For newly-developed medical device products for which no existing classification is available, applicants may either register the products following the regulatory pathway for Class III devices or apply for classification by CFDA. 

    A more significant change is that local manufacturers may start product registration with CFDA before their manufacturing facilities are ready; a measure intended to ease the financial burden of companies in their initial investments for device manufacturing.
  3. Clinical Trials 
    Under the amended Regulation, clinical trials are not required for registration of Class I devices. Certain Class II and Class III devices may be exempted from clinical trials, based on a product catalogue to be developed by CFDA, if they are mature in terms of working mechanism, design and manufacturing process, and their safety and efficacy can be verified through non-clinical evaluation or with data from existing clinical trials or clinical use of the same type of device products. 

    In the meantime, the amended Regulation imposes a new Clinical Trial Approval (CTA) requirement on certain high-risk Class III devices. Class III devices falling into a CFDA-developed catalogue will be subject to these requirements.
  4. Production 
    The amended Regulation does not establish the market authorization holder (MAH) system the industry has been calling for. It continues to impose a Medical Device Production License (MDPL) requirement on local manufacturers of Class II and Class III device. 

    Before applying for a MDPL, companies should first obtain product registration for devices they will manufacture.
  5. Distribution 
    The amended Regulation eliminates the Medical Device Distribution License (MDDL) requirement for Class II device products in China. Going forward, only distribution of Class III products will require a MDDL.
  6. Medical Institution Use 
    The amended Regulation requires medical institutions to keep adequate records of device products they use, and to properly record information relating to implant and other interventional devices to ensure traceability. Also for the first time, the amended Regulation explicitly allows transfer of used medical devices between medical institutions, to the extent the products remain “safe and effective.” 

    Following the issuance of the new Regulation, CFDA has released a number of draft implementing rules on product registration, manufacturing, distribution and clinical studies. Companies operating in China, either directly or through Chinese subsidiaries or third party distributors, should familiarize themselves with this regulatory overhaul.
Sidley Austin LLP - Chen Yang, Lei Li and Ling Su

Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • China
  • Healthcare & Life Sciences
  • Product Regulation & Liability
  • Sidley Austin LLP

Topics

  • Medical device
  • Clinical trial

Popular articles from this firm

  1. Global Drug Pricing and Market Access: What to Expect in 2022 *
  2. Changes in Chinese Securities Law and Draft Data Security Law Affect Cross-Border Investigations *
  3. China publishes new draft Rules on Inserts and Labels for dietary supplements *
  4. Understanding China’s Data Regulatory Regime: What Are Important Data? And Can They Be Transferred Outside Of China? *
  5. Understanding China’s Data Regulatory Regime: China Solicits Public Comments on Certification Rules for Cross-Border Data Processing Activities *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].

Powered by Lexology

Related practical resources PRO

  • How-to guide How-to guide: How to avoid liability for defective products in supply of goods agreements (USA)
  • How-to guide How-to guide: How to assess modern slavery risk in supply chains (USA)
  • How-to guide How-to guide: How to develop a sustainable supply chain (USA)

Related research hubs

  • China
  • Healthcare & Life Sciences
  • Product Regulation & Liability
Back to Top
Resources
  • Daily newsfeed
  • Commentary
  • Q&A
  • Research hubs
  • Learn
  • In-depth
  • Lexy: AI search
Experts
  • Find experts
  • Legal Influencers
  • Firms
  • About Instruct Counsel
More
  • About us
  • Blog
  • Events
  • Popular
Legal
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
Contact
  • Contact
  • RSS feeds
  • Submissions
 
  • Login
  • Register
  • Follow on Twitter
  • Follow on LinkedIn

© Copyright 2006 - 2022 Law Business Research

Law Business Research